Book overview
Coverage is not payment. This single misunderstanding has distorted clinical trial financing for nearly a generation.
For more than two decades, research institutions have relied on Coverage Analyses to distinguish health insurance-billable routine costs from sponsor-obligated research expenses. This book argues that the Coverage Analysis, while essential for complying with anti-fraud laws, has been misapplied as a budgeting tool in recent years, and that the resulting coverage-centric model of clinical trial financing is no longer tenable for research hospitals under current insurance reimbursement methodologies. The Coverage Analysis remains a critical compliance tool for managing research patient charges but changes in health insurance reimbursement have made the tool outdated as a basis for financing.
Drawing on the Medicare Outpatient Prospective Payment System (OPPS) and frameworks established in the U.S. Supreme Court's Escobar and SuperValu cases, the authors demonstrate widespread misalignment of clinical research financial processes-resulting in losses to research sites and increased legal risk. At the heart of the problem is a widely held but empirically false assumption: that insurance coverage equates to insurance payment. Under OPPS, many services Medicare technically "covers" receive minimal or no separate payment, imposing hidden losses on institutions and unanticipated out-of-pocket costs for research patients.
The book advances a new payment-centric model anchored by the Research Payment Analysis (RPA)-a methodological innovation that replaces coverage determinations with empirical reimbursement data as the foundation for sponsor budget negotiations. The book argues that the RPA offers a better opportunity than a Coverage Analysis for research sites to recoup their costs through industry sponsor budget negotiations, improve time-to-activation for trials, and be on a stronger compliance footing.
Clinical Research & Health Insurance has been written for clinical research administrators, hospital revenue cycle professionals, health care lawyers, and compliance officers as well as anyone else seeking a rigorous framework for understanding the intersection of law and clinical trial financing.
